All In Biotech

Free tool

FAERS Monitor: Seasonique

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021840 or its brand name (Seasonique, Ethinyl Estradiol, Levonorgestrel). Reports on generic versions are filed under their own applications.

Reports

200

Serious

73

37% of reports

Hospitalization

23

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue15
  • metrorrhagia14
  • nausea11
  • vaginal haemorrhage11
  • headache10
  • pain9
  • drug ineffective8
  • pruritus8
  • rash8
  • anxiety7
  • product substitution issue7
  • somnolence7
  • vomiting7
  • weight increased7
  • depression6

Reports by year received

View as table
YearReports
20111
20123
20134
201423
201520
201642
201725
201814
201919
202013
20215
20228
20239
20245
20257
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,959 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
metrorrhagiaSignal1486.452.11,098
vaginal haemorrhageSignal1126.715.0247
product substitution issueSignal712.86.265
somnolenceSignal73.71.811
weight increasedSignal73.31.69
depressionSignal62.81.35
anxietySignal72.61.25
pruritusSignal82.21.14
fatigueSignal152.01.27
rash81.91.03
headache101.70.92
vomiting71.60.81
pain91.50.81
nausea111.50.81
drug ineffective80.60.31

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.